RFM Stock Chart & Stats
€0.23
<€0.01(3.18%)
At close: 4:00 PM EDT
€0.23
<€0.01(3.18%)
Day’s Range― - ―
52-Week Range€0.19 - €0.65
Previous CloseN/A
Volume0.00
Average Volume (3M)2.97K
Market Cap
€144.27M
Enterprise Value€55.00
Total Cash (Recent Filing)€47.46M
Total Debt (Recent Filing)€1.28M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 23, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding515,648,600
10 Day Avg. Volume6,875
30 Day Avg. Volume2,971
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside334.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€18.88M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Modest DebtLow leverage and modest total debt reduce financing costs and provide flexibility to support multi-year R&D programs. This durable balance-sheet trait lengthens runway and preserves strategic optionality for partnerships or staged financing despite negative earnings.
Clinical-stage Focus On Inner Ear DisordersA specialized clinical-stage pipeline targeting sensorineural hearing loss and vestibular conditions addresses a concentrated, high unmet-need market. This focused therapeutic niche can create durable competitive advantage via domain expertise, trial data depth, and targeted licensing opportunities.
Partner/collaboration Funding ModelA business model centered on collaborations and licensing provides durable non-product revenue pathways and partner resources. Such arrangements can de-risk clinical programs, supply milestone funding, and reduce sole reliance on equity raises over the medium term.
Bears Say
Sustained Negative Cash GenerationConsistent OCF and FCF outflows indicate sustained cash burn, forcing repeated capital raises. Over months this heightens dilution risk, constrains R&D pacing and makes program execution and timelines dependent on external financing availability.
Revenue Fell To Zero In 2025A complete revenue drop removes any recurring or partner-derived income and reverses prior growth. Structurally, this undermines demonstration of commercial traction and increases reliance on financing, elevating the risk that programs must be delayed or reprioritized.
Deep Losses And Equity ErosionLarge, persistent operating losses and falling equity erode shareholder value and signal heavy dilution over time. Structurally, negative returns impair the company's ability to self-fund development, making progress contingent on continued external capital or partner deals.
Sensorion SAS News
RFM FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.19 and its highest was €0.65 in the past 12 months.
What is Sensorion SAS’s market cap?
Sensorion SAS’s market cap is €144.27M.
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Sep 23, 2026 which is in 54 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Mar 18, 2026. The company reported -€0.04 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.02.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -0.03.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 515,648,600 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€0.04 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went down -2.154%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in DE:RFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sensorion SAS
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
RFM Stock 12 Month Forecast
Average Price Target
€1.00
▲(334.78% Upside)